Development asset linked to BAXTER HEALTHCARE PTY in public FDA and regional records. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
pharma
BAXTER HEALTHCARE PTY
BAXTER HEALTHCARE PTY LTD
BAXTER HEALTHCARE PTY drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
AU HQ
TGA registrant Type
Company details
- Status
- Public
- HQ
- AU
- Programs
- 0
- Drugs
- 6
- Patents
- 0
BAXTER HEALTHCARE PTY pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
BAXTER HEALTHCARE PTY drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to BAXTER HEALTHCARE PTY in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved.